This is a preview of subscription content, log in via an institution to check access.
Literatur
Yosipovitch G et al. Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review. Dermatol Ther (Heidelb) 2023;13:1647-60
Maurer M et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 2022;150:1498-506.e2
Nabavizadeh SH et al. The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria. Asian Pac J Allergy Immunol 2023;41:150-7
Terhorst-Molawi D et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy 2023;78:1269-79
Craig TJ et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1079-90
Aygören-Pürsün E et al. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet 2023;401:458-69
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brehler, R. Urtikaria- und Angioödemtherapie: ein Blick in die Zukunft. hautnah dermatologie 40 (Suppl 1), 14–19 (2024). https://doi.org/10.1007/s15012-024-8357-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15012-024-8357-0